Express Scripts New Flex Formulary Will Prefer Lower-Priced Brand Alternatives
Gilead’s authorized generics for Epclusa and Harvoni will be first alternatives to benefit from preferred coverage on the pharmacy benefit manager's National Preferred Flex Formulary.
You may also be interested in...
Program likely to generate fewer rebates so it remains to be seen whether payers will embrace the new model in a big way.
Approach has been endorsed by Express Scripts as more workable solution than trying to cut list prices for drugs already on the market.
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018.